[1]
“Introducing ‘HEDGE’: sequential intravesical gemcitabine-based thermochemotherapy (HIVEC) plus docetaxel as a potential novel bladder-sparing strategy for BCG-unresponsive non-muscle-invasive bladder cancer”, Arch Ital Urol Androl, vol. 98, no. 3, Sep. 2026, doi: 10.4081/aiua.2026.15738.